Availability and characterization of transgenic and knockout mice with behavioral manifestations: where to look and what to search for

A method for the three-dimensional reconstruction of Neurobiotin™-filled neurons and the location of their synaptic inputs

Here, we describe a robust method for mapping the number and type of neuro-chemically distinct synaptic inputs that a single reconstructed neuron receives. We have used individual hypoglossal motor neurons filled with Neurobiotin by semi-loose seal electroporation in thick brainstem slices. These filled motor neurons were then processed for excitatory and inhibitory synaptic inputs, using immunohistochemical-labeling procedures. For excitatory synapses, we used anti-VGLUT2 to locate glutamatergic pre-synaptic terminals and anti-PSD-95 to locate post-synaptic specializations on and within the surface of these filled motor neurons. For inhibitory synapses, we used anti-VGAT to locate GABAergic pre-synaptic terminals and anti-GABA-A receptor subunit α1 to locate the post-synaptic domain. The Neurobiotin-filled and immuno-labeled motor neuron was then processed for optical sectioning using confocal microscopy. The morphology of the motor neuron including its dendritic tree and the distribution of excitatory and inhibitory synapses were then determined by three-dimensional reconstruction using IMARIS software (Bitplane). Using surface rendering, fluorescence thresholding, and masking of unwanted immuno-labeling, tools found in IMARIS, we were able to obtain an accurate 3D structure of an individual neuron including the number and location of its glutamatergic and GABAergic synaptic inputs. The power of this method allows for a rapid morphological confirmation of the post-synaptic responses recorded by patch-clamp prior to Neurobiotin filling. Finally, we show that this method can be adapted to super-resolution microscopy techniques, which will enhance its applicability to the study of neural circuits at the level of synapses.

Applying advances in neurogenetics to medical practice

The investigation of rare neurogenetic diseases is an example of how a translational science approach may lead to the delineation of complex genetic and biochemical pathways. Thisprocess comprises several intellectual stages. The first step involves the astute identification and clinical description of the unique phenotype, which may lead to obvious pathways or may reveal novel or unexpected mechanisms. As similar patients are identified, the establishment of databases detailing the clinical phenotype may serve to provide clues as to the genetic and biochemical characterization, and identification of the genetic mutation based on patient samples and animal or cellular models. Lastly, attempts to develop and apply therapies based on what has been learned about the biochemical and molecular bases of the disease enables intervention on the individual patient level. Several stages of discovery may overlap or be investigated simultaneously. As examples, this review discusses how this process of investigation has enabled progress in the delineation of several genetic and neurogenetic disorders, including Progeria syndrome, neurodegenerative diseases, muscular dystrophy, Rett syndrome and neurotransmitter disorders. This review attempts to summarize the transition from the bedside-to-bench-to-bedside as a model of bringing such discoveries into the clinical arena, and in doing so addresses the issues that may enhance, or complicate, such a path of discovery, as well as the impact such advances in genetics and genomics may have on the practice of clinical medicine and the role of the physician.

The use of norms of reaction to analyze genotypic and environmental influences on behavior in mice and rats

Norms of reaction (NoRs) represent the phenotypic values of genotypes as functions of environmental parameters and permit the visualization of differences in phenotypic response of different genotypes. NoR graphs can be used to analyze interactions between genotypic and environmental factors during development to produce phenotypes in inbred strains of rats and mice. We describe the main features of NoRs, the history of their use in this context, and discuss several applications in behavioral neuroscience. In addition, we give a test for determining whether distinct strains have different NoRs.

Genotype-environment interactions in mouse behavior: a way out of the problem

In behavior genetics, behavioral patterns of mouse genotypes, such as inbred strains, crosses, and knockouts, are characterized and compared to associate them with particular gene loci. Such genotype differences, however, are usually established in single-laboratory experiments, and questions have been raised regarding the replicability of the results in other laboratories. A recent multilaboratory experiment found significant laboratory effects and genotype x laboratory interactions even after rigorous standardization, raising the concern that results are idiosyncratic to a particular laboratory. This finding may be regarded by some critics as a serious shortcoming in behavior genetics. A different strategy is offered here: (i) recognize that even after investing much effort in identifying and eliminating causes for laboratory differences, genotype x laboratory interaction is an unavoidable fact of life. (ii) Incorporate this understanding into the statistical analysis of multilaboratory experiments using the mixed model. Such a statistical approach sets a higher benchmark for finding significant genotype differences. (iii) Develop behavioral assays and endpoints that are able to discriminate genetic differences even over the background of the interaction. (iv) Use the publicly available multilaboratory results in single-laboratory experiments. We use software-based strategy for exploring exploration (see) to analyze the open-field behavior in eight genotypes across three laboratories. Our results demonstrate that replicable behavioral measures can be practically established. Even though we address the replicability problem in behavioral genetics, our strategy is also applicable in other areas where concern about replicability has been raised.

Murine succinate semialdehyde dehydrogenase deficiency

Inherited succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria) is one of the few neurogenetic disorders of GABA metabolism, and one in which tonic-clonic seizures associate with increased central nervous system GABA and gamma-hydroxybutyrate (GHB). To explore pathomechanisms and develop new preclinical treatment approaches, we developed a murine knockout model of SSADH deficiency. In the absence of intervention, SSADH(-/-) mice suffer 100% mortality at week 3 to 4 of life from generalized tonic-clonic seizures. In this report, we summarize earlier studies indicating disruption of the GABA/glutamine axis in SSADH(-/-) mouse brain, effective pharmacotherapeutic approaches, preliminary gene-therapy results, and electrophysiological analyses of mutant mice. We also present new evidence for oxidative stress in SSADH(-/-) mice, significant alterations of dopamine metabolism, and abnormal neurosteroid levels in brain, potentially implicating the GABA(A) receptor in pathogenesis. In SSADH deficiency, the accumulation of two neuroactive species, GABA and GHB, is significant because GABA is one of the earliest transmitters expressed in mammals, with key roles in synaptogenesis and myelination, whereas GHB displays a vast array of pharmacological actions. The SSADH(-/-) mouse may represent a useful model in which to explore the effect of GABA and GHB accumulation on central nervous system development and function.